uniQure N.V.
QUREuniQure N.V. is a biotechnology company focused on developing gene therapy treatments for genetic and other life-threatening diseases. Founded in the Netherlands, it specializes in delivering gene therapies using adeno-associated virus (AAV) vectors to address rare, serious conditions such as hemophilia and neurological disorders.
Company News
A five-year study of HEMGENIX gene therapy for hemophilia B showed sustained factor IX activity, 90% reduction in bleeding rates, and 94% of patients remaining free from continuous prophylaxis treatment, demonstrating long-term safety and effectiveness.
uniQure received FDA notification that its gene therapy data for AMT-130 does not sufficiently support a Biologics License Application for Huntington's disease treatment, causing significant stock price decline.
The article explores three potential momentum investment opportunities in biotech and battery technology sectors: uniQure, Omeros, and Stardust Power, highlighting their recent developments, financial positions, and analyst expectations.
uniQure (QURE) delivered earnings and revenue surprises of 0.65% and 109.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
The company announced a reorganization that included layoffs.
